COMMUNIQUÉS West-GlobeNewswire

Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04
11/06/2025
Engages with Cytel’s Machine Learning Technology on Data Analysis and Phase 3 Trial Design GLEN ALLEN, Va., June 11, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a [...]
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis
11/06/2025
—Achieves FDA Alignment on CMC and Non-Clinical Toxicology Regulatory Path for Nebokitug in PSC— —Preparations for the Nebokitug PSC Phase 3 Clinical Trial Advance as Discussions with Potential Strategic Partners [...]
R1 Expands Finance and Corporate Development Teams with New Appointments
11/06/2025
Chris Ricaurte Appointed as Chief Financial Officer and Dan Bise Joins as EVP of Corporate Development and Strategy Reflects R1’s Commitment to Continued Expansion and Strategic Evolution MURRAY, Utah, June 11, 2025 ( [...]
Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing
11/06/2025
Facility provides additional funding for next steps of the Company’s growth, including the expected launch of bezuclastinib in 2026 On track to report results from three pivotal trials this year, beginning with SUMMIT [...]
vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series
11/06/2025
HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin , a potential first-in-class oral [...]
Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders
11/06/2025
Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders Agreement is built on a partnership initiated 2022, supporting [...]
uniQure Announces Appointment of Kylie O’Keefe as Chief Customer and Strategy Officer
11/06/2025
~ Proven biotech executive to lead commercialization of AMT-130 in Huntington’s disease ~ LEXINGTON, Mass. and AMSTERDAM, June 11, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company [...]
Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB to Advance Blood-Brain Barrier-Crossing Therapies for Lysosomal Storage Disorders
11/06/2025
Collaboration will leverage Key2Brain’s technology to develop blood-brain barrier-crossing enzyme replacement therapies for lysosomal storage disorders Agreement is built on a partnership initiated in 2022, supporting [...]
Tempest Announces $4.6 Million Registered Direct Offering of Common Stock
11/06/2025
BRISBANE, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company with a pipeline of first-in-class 1 targeted and immune-mediated therapeutics to [...]
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
11/06/2025
In Patients Receiving a Minimum of 55 mCi an Average 5.4 Months of PFS was Observed: Twice the Reported 2.25 Median FLORHAM PARK, N.J., June 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a [...]
Elkedonia clôture un tour d’amorçage de 11 millions d’euros pour le développement de neuroplastogènes comme traitements novateurs contre la dépression et les troubles neuropsychiatriques
11/06/2025
Les fonds permettront d’avancer dans la découverte de traitements potentiellement disruptifs, à action rapide, pour la dépression résistante aux traitements et d'autres troubles neuropsychiatriques. Molécules « first-in [...]
Elkedonia closes EUR 11 million seed round to advance neuroplastogens as novel therapeutics for depression and neuropsychiatric disorders
11/06/2025
Proceeds to advance potentially disruptive, fast-acting therapeutics for treatment-resistant depression and other neuropsychiatric disorders First-in-class, non-addictive, non-hallucinogenic molecules with a non- [...]
Angelini Ventures Invests into €11.25 Million Seed Round for Elkedonia to Advance Neuroplastogens as Novel Therapeutics for Depression and Neuropsychiatric Disorders
11/06/2025
Investment supports the development of first-in-class, non-addictive, non-hallucinogenic molecules with a non-synaptic target, differentiated from existing drugs First start-up company from Argobio’s portfolio to reach [...]
Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025
11/06/2025
Vivoryon Therapeutics N.V. to Report Q1 2025 Financial Results and Operational Progress on June 17, 2025 Halle (Saale) / Munich, Germany, June 11 , 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; [...]
CROSSJECT avance sur le développement de ZEPIZURE® Junior, sa solution pour les crises d'épilepsie chez l'enfant
11/06/2025
Communiqué de presse CROSSJECT avance sur le développement de ZEPIZURE® Junior , sa solution pour les crises d'épilepsie chez l'enfant Annonce la calibration réussie de ZENEO® pour l'utilisation de ZEPIZURE® dans la [...]
CROSSJECT advances on the development of ZEPIZURE® Junior, its solution for epilepsy crises in children
11/06/2025
Press release CROSSJECT advances on the development of ZEPIZURE® Junior , its solution for epilepsy crises in children Announces the effective calibration of ZENEO ® for the use of ZEPIZURE ® in the pediatric population [...]
ONWARD Medical Schedules Webcast to Provide Q1 2025 Business Update and Year-To-Date Highlights
11/06/2025
EINDHOVEN, the Netherlands, June 11, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function and [...]
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
11/06/2025
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines ROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE [...]
Persica strengthens global IP portfolio with EU patent granted for PP353
11/06/2025
London, UK, 11 June 2025 - Persica Pharmaceuticals Limited (Persica), a clinical stage biotechnology company developing a transformative treatment for chronic Low Back Pain (cLBP), today announces that it has been [...]

Pages